Table 3.
Cardiovascular side effects related to Pim kinase inhibitor therapy.
| Drug | Disease | Number of Patients |
Cardiovascular Side Effects (% of Patients) |
Clinical Trial Number/Reference |
|---|---|---|---|---|
| AZD1208 | Solid Tumour | 67 | Thrombocytopenia (5%) Platelet count decreased (25.7%) 3% atrial fibrillation |
NCT01588548 [17] |
| AZD1208 | Acute myeloid leukaemia |
55 | Hypotension (31.3%) | NCT01489722 [17] |
| Pim447 | Multiple myeloma |
13 | Thrombocytopenia (76.9%) Electrocardiogram QT prolonged (15.4%) |
NCT02160951 [18] |
| LGH447 (Pim447) | Multiple Myeloma |
77 | Thrombocytopenia (32.9%) Congestive cardiomyopathy (2.7%) Palpitations (1%) Atrial fibrillation (2.5%) Bradycardia (1%) Sinus bradycardia (2.5%) Tachycardia (53%) |
NCT01456689 [19] |
| LGH447 (Pim447) | AML or High risk Myelodysplastic syndrome |
70 | Thrombocytopenia (32.4%) Platelet count decreased (9%) Disseminated intravascular coagulation (18%) Tachycardia (9%) Sinus bradycardia (9%) Electrocardiogram Qt Prolonged (13.5%) Hypertension (9%) Hypotension (18.8%) |
NCT02078609 [134] |
| SGI-1776 | Relapsed/ Refractory Leukaemia |
14 | Prolonged QtC time Studies withdrawn with no results |
NCT01239108 NCT00848601 [135] |
| TP3654 | Advanced solid tumours |
22 | No reported cardiovascular side effects |
NCT03715504 [130] |
| TP3654 | Myelofibrosis | 8 | No reported cardiovascular side effects |
NCT04176198 [136] |
| INCB053914 | Advanced haematological malignancies |
8 | Thrombocytopenia (15%) |
NCT02587598 [137] |